Quality of clinical and economic evidence in dossier formulary submissions

American Journal of Managed Care

Volumn 13, Issue 7, 2007, Pages 401-407

  Colmenero, Fernando ^a   Sullivan, Sean D ^b   Palmer, Jennifer A ^c   Brauer, Carmen A ^d   Bungay, Kathleen ^c   Watkins, John ^e   Neumann, Peter J ^c  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Premera Blue Cross   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DATA ANALYSIS; DRUG COST; DRUG FORMULARY; DRUG INDICATION; ECONOMIC EVALUATION; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PLANNING; HUMAN; MANAGED CARE; MEDICAL AUDIT; MONEY; OFF LABEL DRUG USE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; SENSITIVITY ANALYSIS; STANDARD; UNITED STATES;

COST-BENEFIT ANALYSIS; DRUG EVALUATION; DRUG INDUSTRY; ECONOMICS, PHARMACEUTICAL; EVIDENCE-BASED MEDICINE; FORMULARIES; GUIDELINE ADHERENCE; HUMANS; MANAGED CARE PROGRAMS; UNITED STATES;

EID: 34447509760     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Sullivan SD, Lyles A, Luce B, Gricar J. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in U.S. health plans and pharmacy benefits management organizations. J Manag Care Pharm. 2001;7:272-282.
2. Neumann PJ. Evidence-based and value-based formulary guidelines. Health Aff (Millwood). 2004;23:124-134.
3. Simon GE, Psaty BM, Hrachovec JB, Mora M. Principles for evidence-based drug formulary policy. J Gen Intern Med. 2005;21:964-968.
4. Luce BR, Lyles CA, Rentz AM. The view from managed care pharmacy. Health Aff (Millwood). 1996;15:168-176.
5. Navarro RP, Blackburn SS. Pharmacy benefit management companies. In: Navarro RP, ed. Managed Care Pharmacy Practice. Gaithersburg, Md: Aspen Publications; 1999:221-242.
6. Mather DB, Sullivan SD, Augenstein D, et al. Incorporating clinical outcomes into drug formulary decisions: a practical approach. Am J Manag Care. 1999;5:277-285.
7. Academy of Managed Care Pharmacy. The AMCP Format for Formulary Submissions, Version 2.1. April 2005. http://www.fmcpnet. org/data/resource/ Format~version2_1~Final_Final.pdf. Accessed September 9, 2006.
8. Cross M. Formulary submission process catches on ... slowly. Manag Care. 2002;11:32-36.
9. Watkins JB, Minshall ME, Sullivan SD. Application of economic analyses in US managed care formulary decisions: a private payer's experience. J Manag Care Pharm. 2006;12:726-735.
10. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. Oxford, England: Oxford University Press; 1996.
11. Medical Letter, Inc. The Medical Letter. http://www.medletter.com. Accessed December 31, 2003.
12. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976-2001. Value Health. 2005;8:3-9.
13. DiMasi JA, Caglarcan E, Wood-Armny MW. Emerging role of pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics. 2001;19:753-766.
14. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA. 2000;283: 2116-2121.
15. Neumann PJ, Claxton K, Weinstein MC. The FDA's regulation of health economic information. Health Aff (Millwood). 2000;19: 129-137.
16. Spooner JJ, Gandhi PK, Connelly SB. AMCP Format dossier requests: manufacturer response and formulary implications for one large health plan. J Manag Care Pharm. 2007;13:37-43.